ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET ANALYSIS

Increasing number of pathogenic bacteria are acquiring antibiotic resistance and new forms of resistance are continuously emerging, which enable clinicians to perform antimicrobial susceptibility testing (AST) on priority. A rapid multiplexed AST platform provides minimum inhibitory concentrations (MICs) within hours at reasonable cost, which enables rapid determination of effective targeted therapy, resulting in short hospital stays, few laboratory tests, and decreasing morbidity and mortality along with associated healthcare expenses.

Increasing launches of tests is expected to drive the market growth during the forecast period

For Instance, in 2019, F. Hoffmann-La Roche Ltd., a research-based healthcare company announced the CE-IVD launch of the cobas MTB-RIF/INH test to detect resistance to antibiotics within tuberculosis DNA.

Moreover, in 2018, Beckman Coulter Inc., a subsidiary of Danaher, announced the commercialization of its DxM MicroScan WalkAway system, a diagnostic solution for bacterial identification and antibiotic susceptibility testing for microbiology laboratories.

Furthermore, antimicrobial susceptibility testing (AST) aims to ensure that suitable antibiotics are prescribed to infected individuals and also helps to identify resistance isolates with defined resistance mechanisms to infection prevention and control, thereby driving growth of the antimicrobial susceptibility testing market.

The global antimicrobial susceptibility testing market is estimated to be valued at US$ 3,525.75  million in 2022 and expected to exhibit a CAGR of 6.4%  over the forecast period (2022-2030).

Figure 1. Global Antimicrobial Susceptibility Testing Market Share (%) in Terms of Value, by Region, 2022

To learn more about this report, request a free sample copy

Increasing awareness initiatives by governments for antimicrobial resistance and its control is expected to aid in the growth of the global antimicrobial susceptibility testing market.

Increasing awareness initiatives by governments for antimicrobial resistance and its control is expected to act as an opportunity for the global antimicrobial susceptibility testing market growth

For instance, the Global Sepsis Alliance, located in the U.S., is a non-profit charity organization with the mission to provide global leadership to reduce the worldwide burden of sepsis. It was founded in 2010 with the aim to raise awareness for sepsis worldwide. More than 100 organizations from all over the world have joined the Global Sepsis Alliance. Sepsis is a potentially life-threatening condition that occurs when the body's response to an infection damages its own tissues.

Figure 2. Global Antimicrobial Susceptibility Testing Market Share (%), by Product Type, 2022

To learn more about this report, request a free sample copy

Global Antimicrobial Susceptibility Testing Market: Restraint

Automated antimicrobial susceptibility testing systems are equipped with highly advanced features and have high prices.The automated antimicrobial susceptibility testing systems have several advantages such as reduced detection time, accuracy of testing, and others; however, the high price of such systems may act as a restraint for the global antimicrobial susceptibility testing market growth.

For instance, according to an article published by the National Center for Biotechnology Information, a series of databases relevant to biotechnology and biomedicine, in July 2020, the high price of molecular testing for antimicrobial susceptibility forms an efficient barrier for the installation of new technologies. According to the same source, testing costs also include those associated with clinical sampling and cultivation in microbiology labs, the processes that are carried out before antimicrobial susceptibility testing (AST). The roughly estimated total cost for mass spectrometry-based AST is € 79 (US$ 83.3) per patient, when the cost of the MALDI-TOF device, reagents, pharmacist time, and the antimicrobial stewardship program are pooled together.

Key Players

Major players operating in the global antimicrobial susceptibility testing market include Thermo Fisher Scientific Inc. and BIOMÉRIEUX, HiMedia Laboratories, Alifax S.r.l. Italy, Creative Diagnostics, Resistell AG, Danaher, Becton, Dickinson and Company, Merck KGaA, Bio-Rad Laboratories, Inc., Bruker, Nissui Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd.,Synbiosis, Mast Group Ltd., ELITechGroup, Flinn Scientific, CONDALAB, Accelerate Diagnostics, Inc., and Zhuhai DL Biotech Co., Ltd.